COST-EFFECTIVENESS OF CEFTOLOZANE/TAZOBACTAM PLUS METRONIDAZOLE AS EMPIRIC THERAPY FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN COLOMBIA

被引：0
|
作者：
Lasalvia, P. [1 ]
Rosselli, D. [2 ]
Castaneda-Cardona, C. [1 ]
Garzon, J. [3 ]
Hernandez, F. [1 ]
Beltran, C. [4 ]
Rojas, M. [4 ]
Lopez, M. C. [5 ]
Sarpong, E. M. [6 ]
机构：
[1] NeuroEconomix, Bogota, Colombia
[2] Pontificia Univ Javeriana, Bogota, Colombia
[3] Hosp San Ignacio, Bogota, Colombia
[4] Merck Sharp & Dohme Ltd, Bogota, Colombia
[5] Merck Sharp & Dhome, Bogota, Colombia
[6] MERCK & CO Inc, Rabway, NJ USA
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PIN36
引用
收藏
页码：S152 / S153
页数：2
相关论文
共 50 条
  • [1] Cost-effectiveness of ceftolozane/tazobactam plus metronidazole compared with piperacillin/tazobactam as empiric therapy for the treatment of complicated intra-abdominal infections based on the in-vitro surveillance of bacterial isolates in the UK
    Prabhu, Vimalanand
    Foo, Jason
    Ahir, Harblas
    Sarpong, Eric
    Merchant, Sanjay
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (08) : 840 - 849
  • [2] COST-EFFECTIVENESS OF CEFTOLOZANE/TAZOBACTAM AS EMPIRIC THERAPY FOR THE TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS IN COLOMBIA
    Lasalvia, P.
    Rosselli, D.
    Castaneda-Cardona, C.
    Garzon, J.
    Hernandez, F.
    Beltran, C.
    Rojas, M.
    Lopez, M. C.
    Sarpong, E. M.
    VALUE IN HEALTH, 2018, 21 : S152 - S152
  • [3] Cost-effectiveness of ceftolozane/tazobactam plus metronidazole versus piperacillin/tazobactam as initial empiric therapy for the treatment of complicated intra-abdominal infections based on pathogen distributions drawn from national surveillance data in the United States
    Prabhu, Vimalanand S.
    Solomkin, Joseph S.
    Medic, Goran
    Foo, Jason
    Borse, Rebekah H.
    Kauf, Teresa
    Miller, Benjamin
    Sen, Shuvayu S.
    Basu, Anirban
    ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL, 2017, 6
  • [4] Cost-effectiveness of ceftolozane/tazobactam plus metronidazole versus piperacillin/tazobactam as initial empiric therapy for the treatment of complicated intra-abdominal infections based on pathogen distributions drawn from national surveillance data in the United States
    Vimalanand S. Prabhu
    Joseph S. Solomkin
    Goran Medic
    Jason Foo
    Rebekah H. Borse
    Teresa Kauf
    Benjamin Miller
    Shuvayu S. Sen
    Anirban Basu
    Antimicrobial Resistance & Infection Control, 6
  • [5] Ceftolozane/tazobactam for the treatment of complicated intra-abdominal infections
    Eckmann, Christian
    Solomkin, Joseph
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (02) : 271 - 280
  • [6] Ceftolozane/tazobactam for the treatment of complicated urinary tract and intra-abdominal infections
    Bassetti, Matteo
    Righi, Elda
    FUTURE MICROBIOLOGY, 2015, 10 (02) : 151 - 160
  • [7] Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections
    Goodlet, Kellie J.
    Nicolau, David P.
    Nailor, Michael D.
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2016, 12 : 1811 - 1826
  • [8] The efficacy and safety of tazobactam/ceftolozane in combination with metronidazole in Japanese patients with complicated intra-abdominal infections
    Mikamo, Hiroshige
    Monden, Kazuteru
    Miyasaka, Yoshiaki
    Horiuchi, Tetsuya
    Fujimoto, Go
    Fukuhara, Takahiro
    Yoshinari, Tomoko
    Rhee, Elizabeth G.
    Shizuya, Toshiyuki
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2019, 25 (02) : 111 - 116
  • [9] Profile of ceftolozane/tazobactam and its potential in the treatment of complicated intra-abdominal infections
    Skalweit, Marion J.
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 2919 - 2925
  • [10] Ceftolozane/Tazobactam: A Review in Complicated Intra-Abdominal and Urinary Tract Infections
    Scott, Lesley J.
    DRUGS, 2016, 76 (02) : 231 - 242
12345